Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions

被引:169
|
作者
Sieber, Martin A. [1 ]
Lengsfeld, Philipp [2 ]
Frenzel, Thomas [1 ]
Golfier, Sven [1 ]
Schmitt-Willich, Heribert [3 ]
Siegmund, Fred [4 ]
Walter, Jakob [4 ]
Weinmann, Hanns-Joachim [1 ]
Pietsch, Hubertus [1 ]
机构
[1] Bayer Schering Pharma AG, TRG Diagnost Imaging, D-13353 Berlin, Germany
[2] Bayer Schering Pharma AG, GMA DG Diagnost Imaging, D-13353 Berlin, Germany
[3] Bayer Schering Pharma AG, GDD Diagnost Imaging, D-13353 Berlin, Germany
[4] Bayer Schering Pharma AG, Nonclin Drug Safety, D-13353 Berlin, Germany
关键词
gadolinium; nephrogenic systemic fibrosis; contrast agents; stability; macrocyclic;
D O I
10.1007/s00330-008-0977-y
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Recent reports suggest that nephrogenic systemic fibrosis (NSF) is associated with the administration of gadolinium (Gd)-based contrast agents (GBCAs) and in particular with the stability of the Gd-complex. The aim of this investigation was to compare GBCAs and their potential to trigger NSF. Forty-two healthy male rats received repeated intravenous injections of six different GBCAs at high doses to simulate the exposure seen in patients with severe renal dysfunction. Histopathological and immunohistochemical analysis of the skin was performed, and the concentrations of Gd, zinc and copper were measured in several tissues by inductive coupled plasma atomic emission spectroscopy. Macroscopic and histological skin changes similar to those seen in NSF patients were only observed in rats receiving Omniscan. In addition, very high concentrations of Gd were observed in the animals treated with Omniscan, and, to a lesser extent, in animals treated with OptiMARK. Significantly lower levels of Gd were found after the treatment with ionic linear agents and even less after the treatment with macrocyclic agents. The data in this investigation strongly suggest that the stability of the Gd-complex is a key factor for the development of NSF-like symptoms in this experimental setting.
引用
收藏
页码:2164 / 2173
页数:10
相关论文
共 36 条
  • [21] Renal function, nephrogenic systemic fibrosis and other adverse reactions associated with gadolinium-based contrast media
    Canga, Ana
    Kislikova, Maria
    Martinez-Galvez, Maria
    Arias, Mercedes
    Fraga-Rivas, Patricia
    Poyatos, Cecilio
    de Francisco, Angel L. M.
    NEFROLOGIA, 2014, 34 (04): : 428 - 438
  • [22] Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: A summary of the medical literature reporting
    Broome, Dale R.
    EUROPEAN JOURNAL OF RADIOLOGY, 2008, 66 (02) : 230 - 234
  • [23] Retrospective analysis of patients for development of nephrogenic systemic fibrosis following conventional angiography using gadolinium-based contrast agents
    Hanno Hoppe
    Sara Spagnuolo
    Johannes M. Froehlich
    Helga Nievergelt
    Hans-Peter Dinkel
    Silvia Gretener
    Harriet C. Thoeny
    European Radiology, 2010, 20 : 595 - 603
  • [24] Novel sorbents for removal of gadolinium-based contrast agents in sorbent dialysis and hemoperfusion: preventive approaches to nephrogenic systemic fibrosis
    Yantasee, Wassana
    Fryxell, Glen E.
    Porter, George A.
    Pattamakomsan, Kanda
    Sukwarotwat, Vichaya
    Chouyyok, Wilaiwan
    Koonsiripaiboon, View
    Xu, Jide
    Raymond, Kenneth N.
    NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2010, 6 (01) : 1 - 8
  • [25] Retrospective analysis of patients for development of nephrogenic systemic fibrosis following conventional angiography using gadolinium-based contrast agents
    Hoppe, Hanno
    Spagnuolo, Sara
    Froehlich, Johannes M.
    Nievergelt, Helga
    Dinkel, Hans-Peter
    Gretener, Silvia
    Thoeny, Harriet C.
    EUROPEAN RADIOLOGY, 2010, 20 (03) : 595 - 603
  • [26] Association of gadolinium based magnetic resonance imaging contrast agents and nephrogenic systemic fibrosis
    Bhave, Gautam
    Lewis, Julia B.
    Chang, Sam S.
    JOURNAL OF UROLOGY, 2008, 180 (03) : 830 - 835
  • [27] Gadolinium-based contrast agents: What we learned from acute adverse events, nephrogenic systemic fibrosis and brain retention
    Baeuerle, Tobias
    Saake, Marc
    Uder, Michael
    ROFO-FORTSCHRITTE AUF DEM GEBIET DER RONTGENSTRAHLEN UND DER BILDGEBENDEN VERFAHREN, 2021, 193 (09): : 1010 - 1018
  • [28] Nephrogenic Systemic Fibrosis in Patients with Chronic Kidney Disease after the Use of Gadolinium-Based Contrast Agents: A Review for the Cardiovascular Imager
    Gallo-Bernal, Sebastian
    Patino-Jaramillo, Nasly
    Calixto, Camilo A.
    Higuera, Sergio A.
    Forero, Julian F.
    Fernandes, Juliano Lara
    Gongora, Carlos
    Gee, Michael S.
    Ghoshhajra, Brian
    Medina, Hector M.
    DIAGNOSTICS, 2022, 12 (08)
  • [29] Application of Gadolinium-Based Contrast Agents and Prevalence of Nephrogenic Systemic Fibrosis in a Cohort of End-Stage Renal Disease Patients on Hemodialysis
    Becker, Stefan
    Walter, Stefan
    Witzke, Oliver
    Kreuter, Alexander
    Kribben, Andreas
    Mitchell, Anna
    NEPHRON CLINICAL PRACTICE, 2012, 121 (1-2): : C91 - C94
  • [30] The need for prophylactic hemodialysis to protect against nephrogenic systemic fibrosis in patients with end-stage renal disease receiving gadolinium-based contrast agents
    Lee, Yeonhee
    Kim, Junghoon
    Kwon, Soie
    Jeong, Jong Cheol
    Joo, Kwon Wook
    Oh, Kook-Hwan
    ACTA RADIOLOGICA, 2023, 64 (08) : 2492 - 2496